Literature DB >> 3281998

Skin eosinophilia in atopic patients.

E Henocq1, B B Vargaftig.   

Abstract

The responses of six atopic and six control patients to the intracutaneous administration of platelet-activating factor (PAF) acether, of the leukocyte secretagogue and chemoattractant f-methionyl-leucyl-phenylalanine (FMLP), and of allergens were studied. Immediate wheal-and-flare skin reactions to allergens and to PAF acether in atopic patients were the same, and when reactions were compared to reactions of nonatopic patients, these reactions to PAF acether and to FMLP were of equivalent intensity. Late-phase reactions were not observed macroscopically with allergen, PAF acether, or FMLP. The cellular responses, assessed by the Rebuck skin window technique, demonstrated a late (24 hours) eosinophilic response to the allergen and to both inflammatory agents, with 33% to 44% of intensively degranulated eosinophils. In comparison, very few, if there were any, eosinophils were observed in the nonatopic patients. Most infiltrated cells were neutrophils. The accumulation of eosinophils in atopic human skin indicates a potent eosinophilotactic activity restricted to the allergic patients. A similar cellular reaction has been observed in lungs from guinea pigs injected with PAF acether or with allergen, and in patients with severe asthma. The chemoattractant activity of FMLP toward eosinophils cannot be accounted for by its histamine-releasing activity and remains to be explained.

Entities:  

Mesh:

Year:  1988        PMID: 3281998     DOI: 10.1016/0091-6749(88)91040-8

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  22 in total

1.  Effect of a 5-lipoxygenase inhibitor and leukotriene antagonist (PF 5901) on PAF-induced airway responses in neonatally immunized rabbits.

Authors:  C M Herd; D Donigi-Gale; T S Shoupe; C P Page
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

Review 2.  The role of eosinophils in asthma.

Authors:  C Kroegel
Journal:  Lung       Date:  1990       Impact factor: 2.584

Review 3.  The role of platelet activating factor in allergic respiratory disease.

Authors:  C P Page
Journal:  Br J Clin Pharmacol       Date:  1990       Impact factor: 4.335

4.  Eosinophil chemotactic activity of topical PAF on the human nasal mucosa.

Authors:  H Klementsson; M Andersson
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 5.  Eosinophils: a review.

Authors:  B J McEwen
Journal:  Vet Res Commun       Date:  1992       Impact factor: 2.459

6.  Proceedings of the British Pharmacological Society, Clinical Pharmacology Section. 5-7 April 1989, Bristol. Abstracts.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1989-08       Impact factor: 4.335

7.  The role of histamine in the acute inflammatory responses to intradermal platelet activating factor.

Authors:  D G Sciberras; S Jordan; D Gill; N S Baber; I James
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

8.  Pretreatment with rh-GMCSF, but not rh-IL3, enhances PAF-induced eosinophil accumulation in guinea-pig airways.

Authors:  S Sanjar; D Smith; M A Kings; J Morley
Journal:  Br J Pharmacol       Date:  1990-07       Impact factor: 8.739

Review 9.  Leukotriene B4 and platelet-activating factor in human skin.

Authors:  L Michel; L Dubertret
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

10.  Platelet-activating factor-induced human eosinophil activation. Generation and release of cyclo-oxygenase metabolites in human blood eosinophils from asthmatics.

Authors:  C Kroegel; H Matthys
Journal:  Immunology       Date:  1993-02       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.